Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer

被引:5
|
作者
Jobim, F. C. [1 ]
Xavier, N. L. [2 ]
Uchoa, D. M. [3 ]
Cruz, D. B. [3 ]
Saciloto, M. [4 ]
Chemello, N. [2 ]
Schwartsmann, G. [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Hosp Clin, Programa Posgrad Med Ciencias Med, BR-90035903 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Hosp Clin, Serv Mastol, BR-90035903 Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Hosp Clin, Serv Patol, BR-90035903 Porto Alegre, RS, Brazil
[4] Univ Fed Santa Maria, Univ Hosp, BR-97119900 Santa Maria, RS, Brazil
关键词
Breast cancer; Vascular endothelial growth factor; Matrix metalloproteinase; Metalloproteinase tissue inhibitors; Sentinel lymph node; MICROVESSEL DENSITY; TUMOR ANGIOGENESIS; PROGNOSTIC-FACTORS; CARCINOMA; MMP-2; EXPRESSION; THERAPY; METASTASIS; SURVIVAL; OVEREXPRESSION;
D O I
10.1590/S0100-879X2009005000016
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Our objective was to determine the presence of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP2) and MMP-9 and specific tissue inhibitors of matrix metalloproteinase (TIMP-1 and TIMP-2) in tumor samples obtained from patients with primary breast cancer. We attempted to correlate these findings with the status of the sentinel lymph node (SLN) and clinical-pathological characteristics such as age, tumor size, histological type, histological grade, and vascular invasion. Tumor samples from 88 patients with primary breast cancer were analyzed. The immunoreactivity of VEGF, MMP-2, MMP-9, TIMP-1, and TIMP-2 in tumors was correlated with clinical and pathological features, as well as SLN status. Nonparametric, Mann-Whittney, Kruskal-Wallis, and Spearmann tests were used. Categorical variables were analyzed by the Pearson test. No statistically significant correlation was found between the amount of VEGF, MMP-2, MMP-9, TIMP-1, and TIMP-2 and the presence of tumor cells in the SLN. However, larger tumor diameter (P < 0.01) and the presence of vascular invasion (P < 0.01) were correlated positively with a positive SLN. A significant correlation of higher VEGF levels (P = 0.04) and lower TIMP-1 levels ( P = 0.04) with ductal histology was also observed. Furthermore, lower TIMP-2 levels showed a statistically significant correlation with younger age (< 50 years) and larger tumor diameter (2.0-5.0 cm). A positive SLN correlated significantly with a larger tumor diameter and the presence of vascular invasion. Higher VEGF and lower TIMP-1 levels were observed in patients with ductal tumors, while higher TIMP-1 levels were observed in lobular tumors.
引用
收藏
页码:979 / 987
页数:9
相关论文
共 50 条
  • [1] Expression of Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases and Vascular Endothelial Growth Factor in Canine Mast Cell Tumours
    Giantin, M.
    Aresu, L.
    Benali, S.
    Arico, A.
    Morello, E. M.
    Martano, M.
    Vascellari, M.
    Castagnaro, M.
    Lopparelli, R. M.
    Zancanella, V.
    Granato, A.
    Mutinelli, F.
    Dacasto, M.
    [J]. JOURNAL OF COMPARATIVE PATHOLOGY, 2012, 147 (04) : 419 - 429
  • [2] Serum matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in rheumatoid arthritis patients treated with repeated infusions of infliximab
    Klimiuk, PA
    Sierakowski, S
    Domyslawska, I
    Gindzienska-Sieskiewicz, E
    Chwiecko, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 410 - 410
  • [3] Tissue inhibitors of matrix metalloproteinases in cancer
    Blavier, L
    Henriet, P
    Imren, S
    DeClerck, YA
    [J]. INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 : 108 - 119
  • [4] Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas
    Iwata, H
    Kobayashi, S
    Iwase, H
    Masaoka, A
    Fujimoto, N
    Okada, Y
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (06): : 602 - 611
  • [5] Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer
    Zhang, Ming
    Teng, Xiao-dan
    Guo, Xin-xin
    Li, Zhi-gao
    Han, Ji-guang
    Yao, Lei
    [J]. BREAST, 2013, 22 (03): : 330 - 334
  • [6] Matrix metalloproteinases and vascular endothelial growth factor expression in canine leukaemias
    Arico, Arianna
    Giantin, Mery
    Gelain, Mariaelena
    Riondato, Fulvio
    Mortarino, Michele
    Comazzi, Stefano
    Dacasto, Mauro
    Castagnaro, Massimo
    Aresu, Luca
    [J]. VETERINARY JOURNAL, 2013, 196 (02): : 260 - 262
  • [7] Regulation of matrix metalloproteinases and their tissue inhibitors by transforming growth factor-β
    Lin, HY
    Wang, HM
    Zhu, C
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2003, 30 (01) : 7 - 12
  • [8] Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
    Borden, P
    Heller, RA
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2): : 159 - 178
  • [9] Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease
    Zakiyanov, Oskar
    Kalousova, Marta
    Zima, Tomas
    Tesar, Vladimir
    [J]. ADVANCES IN CLINICAL CHEMISTRY, VOL 105, 2021, 105 : 141 - 212
  • [10] Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165
    Hashimoto, G
    Inoki, I
    Fujii, Y
    Aoki, T
    Ikeda, E
    Okada, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) : 36288 - 36295